{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:59:34Z","timestamp":1767772774366,"version":"3.44.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Heterologous prime\u2013boost vaccination has emerged as a promising approach to enhance immune responses by combining vaccines with complementary mechanisms of antigen delivery and immune activation. Here, we evaluated the immunogenicity of heterologous regimens combining the licensed inactivated SARS-CoV-2 vaccine (VLA2001) with the replication-deficient Orf virus-based vector vaccine (Prime-2-CoV). Using a mouse model, we compared these regimens to homologous vaccinations with each vaccine alone. Among the combinations tested, priming with VLA2001 followed by boosting with Prime-2-CoV induced the strongest spike-specific antibody responses, superior ACE2-binding inhibition against pre-Omicron variants, and robust Th1-biased immunity, with robust CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T-cell responses. This sequence also enhanced nucleocapsid-specific immunity, underscoring the benefit of multiantigen targeting. These findings highlight the immunological synergy between inactivated whole-virus and ORFV vector vaccines and support the strategic use of Prime-2-CoV as a potent heterologous booster. The ORFV platform\u2019s favorable safety profile and Th1-polarizing capacity make it a valuable candidate for future heterologous vaccine strategies beyond SARS-CoV-2.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1675859","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:31:52Z","timestamp":1758173512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice"],"prefix":"10.3389","volume":"16","author":[{"given":"Alena","family":"Reguzova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Haug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Fandrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Dulovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41392-024-01917-x","article-title":"Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/vaccines13030308","article-title":"Vaccination strategies: mixing paths versus matching tracks","volume":"13","author":"Livieratos","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975980","article-title":"Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients","volume":"12","author":"Benitez Fuentes","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/v14122727","article-title":"Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy","volume":"14","author":"Wang","year":"2022","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12979-024-00466-9","article-title":"Repeated COVID-19 mRNA vaccination results in IgG4 class switching and decreased NK cell activation by S1-specific antibodies in older adults","volume":"21","author":"Gelderloos","year":"2024","journal-title":"Immun Ageing"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s43556-025-00258-7","article-title":"A promising mRNA vaccine derived from the JN.1 spike protein confers protective immunity against multiple emerged Omicron variants","volume":"6","author":"Ao","year":"2025","journal-title":"Mol BioMed"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S464720","article-title":"Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice","volume":"19","author":"Li","year":"2024","journal-title":"Int J Nanomed"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01463-x","article-title":"A \u2018mix and match\u2019 approach to SARS-CoV-2 vaccination","volume":"27","author":"Deming","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/idr14040057","article-title":"Mix-and-match COVID-19 vaccinations (Heterologous boost): A review","volume":"14","author":"Garg","year":"2022","journal-title":"Infect Dis Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.06.009","article-title":"Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1\/2 clinical trial in healthy adults","volume":"85","author":"Lazarus","year":"2022","journal-title":"J Infect"},{"key":"B15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41541-024-00981-2","article-title":"A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2","volume":"9","author":"Reguzova","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3390\/vaccines12111288","article-title":"First-in-human phase I trial to assess the safety and immunogenicity of an orf virus-based COVID-19 vaccine booster","volume":"12","author":"Esen","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"109831","DOI":"10.1016\/j.vetmic.2023.109831","article-title":"ORFV entry into host cells via clathrin-mediated endocytosis and macropinocytosis","volume":"284","author":"Tang","year":"2023","journal-title":"Vet Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873351","article-title":"Orf virus-based vectors preferentially target professional antigen-presenting cells, activate the STING pathway and induce strong antigen-specific T cell responses","volume":"13","author":"Muller","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/vaccines12050492","article-title":"Pharmacokinetic and environmental risk assessment of prime-2-coV, a non-replicating orf virus-based vaccine against SARS-coV-2","volume":"12","author":"Metz","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/rmv.70038","article-title":"Advancing ORFV-based therapeutics to the clinical stage","volume":"35","author":"Helmold","year":"2025","journal-title":"Rev Med Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/v7031505","article-title":"Molecular genetic analysis of orf virus: a poxvirus that has adapted to skin","volume":"7","author":"Fleming","year":"2015","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1656(99)00141-8","article-title":"Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts","volume":"73","author":"Rziha","year":"1999","journal-title":"J Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1439-0450.2002.00539.x","article-title":"Parapoxviruses: from the lesion to the viral genome","volume":"49","author":"Buttner","year":"2002","journal-title":"J Vet Med B Infect Dis Vet Public Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/v11020127","article-title":"Genomic characterization of orf virus strain D1701-V (Parapoxvirus) and development of novel sites for multiple transgene expression","volume":"11","author":"Rziha","year":"2019","journal-title":"Viruses"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02470-12","article-title":"A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein","volume":"87","author":"Amann","year":"2013","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e83802","DOI":"10.1371\/journal.pone.0083802","article-title":"New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus","volume":"8","author":"Rohde","year":"2013","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.12.004","article-title":"Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs","volume":"28","author":"van Rooij","year":"2010","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.1.314-325.2005","article-title":"Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant","volume":"79","author":"Henkel","year":"2005","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2410574","DOI":"10.1080\/21645515.2024.2410574","article-title":"A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity","volume":"20","author":"Klinkardt","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0010459","DOI":"10.1371\/journal.pntd.0010459","article-title":"Host transcriptomic profiling of CD-1 outbred mice with severe clinical outcomes following infection with Orientia tsutsugamushi","volume":"16","author":"Thiriot","year":"2022","journal-title":"PloS Negl Trop Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1038\/s41598-022-10987-2","article-title":"COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants","volume":"12","author":"Junker","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","article-title":"Immune response to SARS-CoV-2 variants of concern in vaccinated individuals","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac498","article-title":"Antibody binding and angiotensin-converting enzyme 2 binding inhibition is significantly reduced for both the BA.1 and BA.2 omicron variants","volume":"76","author":"Junker","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17661","article-title":"STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease","volume":"58","author":"Woelfel","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/vaccines12070774.","article-title":"Systemic and mucosal immunogenicity of monovalent XBB.1.5-adapted COVID-19 mRNA vaccines in patients with inflammatory bowel disease","volume":"12","author":"Woelfel","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00716-1","article-title":"Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast","volume":"22","author":"Kent","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02962-3","article-title":"Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children","volume":"30","author":"Zhong","year":"2024","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","article-title":"SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees","volume":"6","author":"Geers","year":"2021","journal-title":"Sci Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.06.018","article-title":"Nucleocapsid-specific antibodies as a correlate of protection against SARS-CoV-2 reinfection in children","volume":"87","author":"Dowell","year":"2023","journal-title":"J Infect"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e162282","DOI":"10.1172\/JCI162282","article-title":"Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody","volume":"132","author":"Dangi","year":"2022","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100811","DOI":"10.1016\/j.xcrm.2022.100811","article-title":"Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy","volume":"3","author":"Herman","year":"2022","journal-title":"Cell Rep Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"115512","DOI":"10.1016\/j.celrep.2025.115512","article-title":"Transfer of SARS-CoV-2 nucleocapsid protein to uninfected epithelial cells induces antibody-mediated complement deposition","volume":"44","author":"Fahoum","year":"2025","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/pathogens13121109","article-title":"Detrimental effects of anti-nucleocapsid antibodies in SARS-coV-2 infection, reinfection, and the post-acute sequelae of COVID-19","volume":"13","author":"Nakayama","year":"2024","journal-title":"Pathogens"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095910","article-title":"Pathways of antigen processing","volume":"31","author":"Blum","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791753","article-title":"SARS-coV-2 N protein induces acute lung injury in mice via NF-kB activation","volume":"12","author":"Xia","year":"2021","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1932","article-title":"Orf virus infection","volume":"27","author":"Bergqvist","year":"2017","journal-title":"Rev Med Virol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0147-9571(96)00045-8","article-title":"The immune and inflammatory response to orf virus","volume":"20","author":"Haig","year":"1997","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0168-1702(02)00117-X","article-title":"Immunity and counter-immunity during infection with the parapoxvirus orf virus","volume":"88","author":"Haig","year":"2002","journal-title":"Virus Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e29454","DOI":"10.1002\/jmv.29454","article-title":"A superior heterologous prime-boost vaccination strategy against COVID-19: A bivalent vaccine based on yeast-derived RBD proteins followed by a heterologous vaccine","volume":"96","author":"Liu","year":"2024","journal-title":"J Med Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142394","article-title":"Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2052525","DOI":"10.1080\/21645515.2022.2052525","article-title":"Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines","volume":"18","author":"Cohen","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.01.032","article-title":"Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals","volume":"41","author":"Mallah","year":"2023","journal-title":"Vaccine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.06.022","article-title":"Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial","volume":"87","author":"Taucher","year":"2023","journal-title":"J Infect"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00642-8","article-title":"Lessons from vaccine-induced immune thrombotic thrombocytopenia","volume":"21","author":"Kelton","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","article-title":"Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models","volume":"14","author":"Hajnik","year":"2022","journal-title":"Sci Transl Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e00647-20","DOI":"10.1128\/JVI.00647-20","article-title":"The nucleocapsid protein of SARS-coV-2: a target for vaccine development","volume":"94","author":"Dutta","year":"2020","journal-title":"J Virol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.06.046","article-title":"Nucleocapsid as a next-generation COVID-19 vaccine candidate","volume":"122","author":"Oronsky","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41541-021-00321-8","article-title":"Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters","volume":"6","author":"Jia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"Chiuppesi","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B65","doi-asserted-by":"publisher","first-page":"eabo0226","DOI":"10.1126\/sciimmunol.abo0226","article-title":"A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection","volume":"7","author":"Routhu","year":"2022","journal-title":"Sci Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"B68","doi-asserted-by":"publisher","first-page":"21254940","DOI":"10.1101\/2021.04.05.21254940","article-title":"Prime hAd5 spike + Nucleocapsid vaccination induces ten-fold increases in mean T-cell responses in phase 1 subjects that are sustained against spike variants","author":"Sieling","year":"2021","journal-title":"medRxiv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-coV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/procel\/pwae007","article-title":"Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion","volume":"15","author":"Xue","year":"2024","journal-title":"Protein Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02223-y","article-title":"SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants","volume":"52","author":"Hattab","year":"2024","journal-title":"Infection"},{"key":"B72","doi-asserted-by":"publisher","first-page":"109664","DOI":"10.1016\/j.celrep.2021.109664","article-title":"Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2","volume":"36","author":"Dangi","year":"2021","journal-title":"Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001400","article-title":"Cutting edge: mouse SARS-coV-2 epitope reveals infection and vaccine-elicited CD8 T cell responses","volume":"206","author":"Joag","year":"2021","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e2102775118","DOI":"10.1073\/pnas.2102775118","article-title":"Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy","volume":"118","author":"Wang","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B76","doi-asserted-by":"publisher","first-page":"6792","DOI":"10.1038\/s41467-022-34571-4","article-title":"Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"D1512\u2013D1518","DOI":"10.1093\/nar\/gkac1005","article-title":"LitCovid in 2022: an information resource for the COVID-19 literature","volume":"6","author":"Chen","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e150012","DOI":"10.1172\/jci.insight.150012","article-title":"Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay","volume":"6","author":"Lopez","year":"2021","journal-title":"JCI Insight"},{"key":"B79","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbt.2021.10.002","article-title":"A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies","volume":"66","author":"Mravinacova","year":"2022","journal-title":"N Biotechnol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-coV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines - fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00461-z","article-title":"Tissue resident memory T cells in the respiratory tract","volume":"15","author":"Zheng","year":"2022","journal-title":"Mucosal Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-coV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:31:53Z","timestamp":1758173513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2025.1675859"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1675859","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1675859"}}